Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.44
-0.08 (-1.45%)
Jun 16, 2025, 4:00 PM - Market closed
Amylyx Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | -1.27 | 87.37 | 380.79 | 22.23 | 0.29 | 0.65 | Upgrade
|
| Revenue Growth (YoY) | - | -77.05% | 1612.94% | 7700.00% | -56.15% | -54.42% | Upgrade
|
| Cost of Revenue | 97.82 | 228.72 | 153.63 | 96.44 | 44.04 | 24.59 | Upgrade
|
| Gross Profit | -99.09 | -141.35 | 227.16 | -74.21 | -43.76 | -23.94 | Upgrade
|
| Selling, General & Admin | 72.26 | 114.33 | 188.36 | 127.13 | 38.93 | 15.06 | Upgrade
|
| Research & Development | 36.2 | 36.2 | - | - | - | - | Upgrade
|
| Operating Expenses | 108.46 | 150.53 | 188.36 | 127.13 | 38.93 | 15.06 | Upgrade
|
| Operating Income | -207.55 | -291.88 | 38.8 | -201.34 | -82.69 | -39.01 | Upgrade
|
| Interest Expense | - | - | - | - | - | -2.29 | Upgrade
|
| Interest & Investment Income | 11.71 | 13.81 | 16.16 | 4.29 | 0.04 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -11.07 | -11.07 | -10.6 | -2.61 | 0.07 | -1.27 | Upgrade
|
| EBT Excluding Unusual Items | -206.5 | -289.14 | 44.36 | -199.66 | -82.58 | -42.55 | Upgrade
|
| Merger & Restructuring Charges | -22.85 | -22.85 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.86 | 9.86 | 9.94 | 2.06 | -0.12 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -5.23 | 0.27 | Upgrade
|
| Pretax Income | -219.49 | -302.14 | 54.3 | -197.6 | -87.93 | -42.28 | Upgrade
|
| Income Tax Expense | -0.64 | -0.39 | 5.03 | 0.77 | - | - | Upgrade
|
| Net Income | -218.86 | -301.74 | 49.27 | -198.38 | -87.93 | -42.28 | Upgrade
|
| Net Income to Common | -218.86 | -301.74 | 49.27 | -198.38 | -87.93 | -42.28 | Upgrade
|
| Shares Outstanding (Basic) | 73 | 68 | 67 | 58 | 7 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 73 | 68 | 70 | 58 | 7 | 6 | Upgrade
|
| Shares Change (YoY) | 7.53% | -2.64% | 19.65% | 788.13% | 8.37% | 3.20% | Upgrade
|
| EPS (Basic) | -3.01 | -4.43 | 0.73 | -3.39 | -13.35 | -6.96 | Upgrade
|
| EPS (Diluted) | -3.02 | -4.43 | 0.70 | -3.39 | -13.35 | -6.96 | Upgrade
|
| Free Cash Flow | -243.29 | -204.01 | 10.68 | -182.4 | -75.15 | -36.85 | Upgrade
|
| Free Cash Flow Per Share | -3.35 | -2.99 | 0.15 | -3.12 | -11.41 | -6.06 | Upgrade
|
| Gross Margin | - | -161.78% | 59.66% | - | - | - | Upgrade
|
| Operating Margin | - | -334.07% | 10.19% | -905.72% | -29013.33% | -6000.77% | Upgrade
|
| Profit Margin | - | -345.36% | 12.94% | -892.38% | -30852.98% | -6504.61% | Upgrade
|
| Free Cash Flow Margin | - | -233.50% | 2.80% | -820.50% | -26369.12% | -5668.92% | Upgrade
|
| EBITDA | -206.81 | -290.98 | 39.89 | -200.85 | -82.64 | -39 | Upgrade
|
| EBITDA Margin | - | - | 10.48% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.75 | 0.9 | 1.09 | 0.49 | 0.05 | 0 | Upgrade
|
| EBIT | -207.55 | -291.88 | 38.8 | -201.34 | -82.69 | -39.01 | Upgrade
|
| EBIT Margin | - | - | 10.19% | - | - | - | Upgrade
|
| Effective Tax Rate | - | - | 9.26% | - | - | - | Upgrade
|
| Revenue as Reported | - | - | - | 22.23 | 0.29 | - | Upgrade
|
| Advertising Expenses | - | 2.7 | 9.5 | 4.4 | - | - | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.